Stockscreener 앱 받기
9.00
2.07%
-0.19
시간 외 거래:
8.96
-0.04
-0.44%
Viatris Inc 주식(VTRS)의 최신 뉴스
Xanax Maker Partially Blocks Hemp Co.'s 'Canvax' TM - Law360
What makes Viatris Inc. stock attractive to long term investorsSmart Safety Strategy With Real Data Analysis - Newser
Anchoring Your Portfolio: Is VTRS Stock a Safe Harbor? - investchronicle.com
What data driven models say about Viatris Inc.’s futureHigh Return Trade Roadmap with Setup Filters - Newser
Influenza Vaccine Market is projected to grow to US$ 13.75 - openPR.com
Lidocaine Vial Market Set to Witness Significant Growth by 2033 | - openPR.com
Neurovascular Guidewires Market Outlook 2025 to 2035: Growth - openPR.com
US Court Agrees To Throw Out Viatris Wegovy Infringement Case - insights.citeline.com
How to interpret RSI for Viatris Inc. stockMomentum Stocks with Breakout Potential - Newser
Why Viatris Inc. stock attracts strong analyst attention Daily Trade Monitor with Pattern Alerts - Newser
Why is Viatris Inc. stock attracting strong analyst attentionInvest in high-yield stocks with confidence - jammulinksnews.com
How strong is Viatris Inc. company’s balance sheetAchieve rapid financial growth with expert help - jammulinksnews.com
Should I hold or sell Viatris Inc. stock in 2025Maximize portfolio value with expert tips - jammulinksnews.com
How does Viatris Inc. compare to its industry peersFree Bull & Bear Market Updates - jammulinksnews.com
How volatile is Viatris Inc. stock compared to the marketUnprecedented profit potential - jammulinksnews.com
Competitive Positioning of Viatris Inc.: Is It Leading or LaggingFree Consultation - Newser
Why Viatris Inc. stock attracts strong analyst attentionSmart High Yield Swing Trades - metal.it
What institutions are buying Viatris Inc. stock nowConsistent double returns - jammulinksnews.com
What analysts say about Viatris Inc. stockTremendous wealth creation - PrintWeekIndia
What drives Viatris Inc. stock priceMarket-crushing profits - PrintWeekIndia
Bausch Health adds two pharmaceutical industry veterans to board By Investing.com - Investing.com Nigeria
Bausch Health Expands Leadership: Ex-Viatris CEO and Bristol Myers Legal Chief Join Board in Strategic Move - Stock Titan
Novo Nordisk defeated in Wegovy patent dispute by Viatris - Yahoo Finance
Is Viatris Inc. a good long term investmentOutperformance with explosive growth - Autocar Professional
Novo Nordisk loses Wegovy patent fight against generics maker Viatris - Endpoints News
Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit - Bloomberg Law News
Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha
What to Expect From Viatris' Next Quarterly Earnings Report - MSN
What To Expect From Viatris' Next Quarterly Earnings Report - Barchart.com
VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN
Viatris down on late-stage trial setback for eye disorder therapy - MSN
Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq
Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance
Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter
Viatris Inc. (VTRS) Stock Analysis: A Deep Dive Into Its 28% Potential Upside For Investors - DirectorsTalk Interviews
Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com
Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest
Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest
Trend Tracker for (VTRS) - news.stocktradersdaily.com
Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest
4.47%
1.92%
자본화:
|
볼륨(24시간):